{
    "@graph": [
        {
            "@id": "https://www.tib.eu/de/suchen/id/TIBKAT%3A1738403114",
            "@type": "bibo:Book",
            "P1053": "1 Online-Ressource",
            "contributor": "Wasserman, Melissa F.",
            "creator": [
                "Frakes, Michael D.",
                "National Bureau of Economic Research"
            ],
            "description": [
                "Campusweiter Zugriff (Universit\u00e4t Hannover) - Vervielf\u00e4ltigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots.",
                "illustrations (black and white)"
            ],
            "identifier": [
                "(firstid)KEP:05952426X",
                "(ppn)1738403114",
                "(doi)10.3386/w27579"
            ],
            "publisher": "National Bureau of Economic Research",
            "subject": "(classificationName=linseach:automatic)cet",
            "title": "Investing in Ex Ante Regulation : Evidence from Pharmaceutical Patent Examination",
            "abstract": "The debate surrounding escalating prescription drug prices has increasingly focused on the legitimacy of the practice of brand-name manufacturers receiving patent protection on peripheral features of the drug such as the route of administration, as opposed to just the active-ingredient itself.  The key question is whether these later-obtained, secondary patents protect novel features and represent true innovation or, instead, provide little to no innovative benefit and improperly delay generic entry.  In this paper, we explore how the Patent Office may improve the quality of the secondary patents issued--thereby reducing the degree of unnecessary and harmful delays of generic entry--by giving examiners more time to review patent applications.  Our findings suggest that current examiner time allocations are causing patent examiners to issue low quality secondary patents on the margin.  We further set forth evidence suggesting that the costs to investing in greater ex ante scrutiny of secondary pharmaceutical patent applications by the Patent Office are greatly outweighed by the benefits, which include the avoidance of downstream litigation expenses and gains to consumer and total surplus from reduced drug prices",
            "dcterms:contributor": "Technische Informationsbibliothek (TIB)",
            "isPartOf": "(collectioncode)ZDB-194-NBW",
            "issued": "2020",
            "language": "http://id.loc.gov/vocabulary/iso639-1/en",
            "license": "open access",
            "medium": "rda:termList/RDACarrierType/1018",
            "volume": "no. w27579",
            "isLike": "doi:10.3386/w27579",
            "P30128": "NBER working paper series",
            "P60163": "Cambridge, Mass"
        }
    ],
    "@id": "urn:x-arq:DefaultGraphNode",
    "@context": {
        "abstract": "http://purl.org/dc/terms/abstract",
        "creator": "http://purl.org/dc/elements/1.1/creator",
        "contributor": "http://purl.org/dc/elements/1.1/contributor",
        "license": "http://purl.org/dc/terms/license",
        "title": "http://purl.org/dc/elements/1.1/title",
        "medium": {
            "@id": "http://purl.org/dc/terms/medium",
            "@type": "@id"
        },
        "P60163": "http://www.rdaregistry.info/Elements/u/#P60163",
        "volume": "http://purl.org/ontology/bibo/volume",
        "issued": "http://purl.org/dc/terms/issued",
        "isPartOf": "http://purl.org/dc/terms/isPartOf",
        "P1053": "http://iflastandards.info/ns/isbd/elements/P1053",
        "publisher": "http://purl.org/dc/elements/1.1/publisher",
        "identifier": "http://purl.org/dc/elements/1.1/identifier",
        "language": {
            "@id": "http://purl.org/dc/terms/language",
            "@type": "@id"
        },
        "P30128": "http://www.rdaregistry.info/Elements/m/#P30128",
        "subject": "http://purl.org/dc/elements/1.1/subject",
        "description": "http://purl.org/dc/elements/1.1/description",
        "isLike": {
            "@id": "http://umbel.org/umbel#isLike",
            "@type": "@id"
        },
        "umbel": "http://umbel.org/umbel#",
        "rdau": "http://www.rdaregistry.info/Elements/u/#",
        "owl": "http://www.w3.org/2002/07/owl#",
        "dcterms": "http://purl.org/dc/terms/",
        "bibo": "http://purl.org/ontology/bibo/",
        "rdam": "http://www.rdaregistry.info/Elements/m/#",
        "gnd": "http://d-nb.info/gnd/",
        "isbd": "http://iflastandards.info/ns/isbd/elements/",
        "rda": "http://rdvocab.info/",
        "doi": "https://doi.org/"
    }
}